Jan Skvarka - Net Worth and Insider Trading

Jan Skvarka Net Worth

The estimated net worth of Jan Skvarka is at least $189,961 dollars as of 2024-11-10. Jan Skvarka is the Director of Zentalis Pharmaceuticals Inc and owns about 47,970 shares of Zentalis Pharmaceuticals Inc (ZNTL) stock worth over $189,961. Jan Skvarka is also the President and CEO of Trillium Therapeutics Inc and owns about 0 shares of Trillium Therapeutics Inc (TRIL) stock worth over $0. Details can be seen in Jan Skvarka's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jan Skvarka has not made any transactions after 2023-09-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Jan Skvarka

To

Jan Skvarka Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jan Skvarka owns 2 companies in total, including Zentalis Pharmaceuticals Inc (ZNTL) , and Monte Rosa Therapeutics Inc (GLUE) .

Click here to see the complete history of Jan Skvarka’s form 4 insider trades.

Insider Ownership Summary of Jan Skvarka

Ticker Comapny Transaction Date Type of Owner
ZNTL Zentalis Pharmaceuticals Inc 2023-09-11 director
GLUE Monte Rosa Therapeutics Inc 2023-03-23 director

Jan Skvarka Latest Holdings Summary

Jan Skvarka currently owns a total of 2 stocks. Among these stocks, Jan Skvarka owns 47,970 shares of Zentalis Pharmaceuticals Inc (ZNTL) as of September 11, 2023, with a value of $189,961 and a weighting of 100%. Jan Skvarka also owns 0 shares of Trillium Therapeutics Inc (TRIL) as of January 14, 2021, with a value of $0 and a weighting of 0%.

Latest Holdings of Jan Skvarka

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ZNTL Zentalis Pharmaceuticals Inc 2023-09-11 47,970 3.96 189,961
TRIL Trillium Therapeutics Inc 2021-01-14 0 18.44 0

Holding Weightings of Jan Skvarka


Jan Skvarka Form 4 Trading Tracker

According to the SEC Form 4 filings, Jan Skvarka has made a total of 1 transactions in Zentalis Pharmaceuticals Inc (ZNTL) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Zentalis Pharmaceuticals Inc is the sale of 5,000 shares on September 11, 2023, which brought Jan Skvarka around $125,250.

According to the SEC Form 4 filings, Jan Skvarka has made a total of 1 transactions in Trillium Therapeutics Inc (TRIL) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Trillium Therapeutics Inc is the sale of 25,000 shares on January 14, 2021, which brought Jan Skvarka around $375,750.

Insider Trading History of Jan Skvarka

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jan Skvarka Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jan Skvarka Ownership Network

Ownership Network List of Jan Skvarka

No Data

Ownership Network Relation of Jan Skvarka

Insider Network Chart

Jan Skvarka Owned Company Details

What does Zentalis Pharmaceuticals Inc do?

Who are the key executives at Zentalis Pharmaceuticals Inc?

Jan Skvarka is the director of Zentalis Pharmaceuticals Inc. Other key executives at Zentalis Pharmaceuticals Inc include Chief Financial Officer Melissa B, Epperly , General Counsel Andrea Paul , and Chief Medical Officer Carrie Brownstein .

Zentalis Pharmaceuticals Inc (ZNTL) Insider Trades Summary

Over the past 18 months, Jan Skvarka made 1 insider transaction in Zentalis Pharmaceuticals Inc (ZNTL) with a net sale of 5,000. Other recent insider transactions involving Zentalis Pharmaceuticals Inc (ZNTL) include a net sale of 50,090 shares made by Cam Gallagher , a net sale of 16,724 shares made by Melissa B, Epperly , and a net sale of 86,068 shares made by Kevin D. Bunker .

In summary, during the past 3 months, insiders sold 1,603 shares of Zentalis Pharmaceuticals Inc (ZNTL) in total and bought 0 shares, with a net sale of 1,603 shares. During the past 18 months, 178,364 shares of Zentalis Pharmaceuticals Inc (ZNTL) were sold and 22,000 shares were bought by its insiders, resulting in a net sale of 156,364 shares.

Zentalis Pharmaceuticals Inc (ZNTL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Zentalis Pharmaceuticals Inc Insider Transactions

No Available Data

Jan Skvarka Mailing Address

Above is the net worth, insider trading, and ownership report for Jan Skvarka. You might contact Jan Skvarka via mailing address: C/o Trillium Therapeutics Inc., 2488 Dunwin Drive, Mississauga A6 L5l 1j9.